Blue Earth Therapeutics has entered a clinical research partnership with University College London in the UK to progress the clinical development of an Alpha-labelled Radioligand Therapy (RLT) for prostate cancer.
This partnership focuses on executing a Phase I/II clinical trial aimed at assessing the safety, tolerability, and efficacy of ²²⁵Ac-rhPSMA-10.1 in male patients with advanced prostate cancer.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial will enrol male patients with metastatic castrate-resistant prostate cancer who have responded to prior lutetium 177 (¹⁷⁷Lu)-PSMA therapy.
To be conducted at the UCL Cancer Institute by the Treatment Resistance Group, the trial will be led by professor Gerhardt Attard.
²²⁵Ac-rhPSMA-10.1 is said to be the second investigational compound in Blue Earth Therapeutics’ pipeline.
It uses radiohybrid PSMA technology, enabling the creation of radiopharmaceutical therapeutics that can be labelled with beta- or alpha-emitting isotopes.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDuring development, the pharmacokinetic profile of rhPSMA-10.1 was optimised to enhance the retention of radioactivity in tumour cells while minimising exposure to normal tissues.
The combination of these properties with longer-lived isotopes, such as ²²⁵Ac, could potentially deliver significantly higher doses of radiation directly to cancer cells.
Blue Earth is also conducting a trial of rhPSMA-10.1 labelled with the beta-emitting ¹⁷⁷Lu.
The company is now expanding its research by labelling the compound with the alpha-emitting isotope ²²⁵Ac.
Blue Earth Therapeutics CEO David Gauden said: “Our goal at Blue Earth Therapeutics is to deliver precise, targeted therapy specific to a patient’s condition.
“This collaboration aims to rapidly translate alpha-labelled rhPSMA-10.1 from the laboratory to the clinic, with the hope of helping patients who have advanced prostate cancer. We are delighted to collaborate with an illustrious academic institution such as UCL which is regularly ranked in the top ten academic institutions globally, and look forward to working with Professor Attard and his group on this important UK clinical research initiative.”
